PSEUDOVITELLIFORM MACULOPATHY SECONDARY TO BRAF AND MEK INHIBITORS IN A PATIENT WITH METASTASIC MELANOMA

被引：0
|
作者：
Alba-Linero, C. [1 ]
Rocha De Lossada, C. [1 ]
Delgado-Fernandez, A. S. [1 ]
Jodar-Marquez, M. [1 ]
Calvo De Mora, M. Rodriguez [1 ]
Berciano-Guerrero, M. A. [2 ]
机构：
[1] Hosp Reg Malaga, Plaza Hosp Civil, Ophthalmol Dept, Malaga 29009, Spain
[2] Hosp Reg Malaga, Oncol Dept, Malaga, Spain
来源：
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS | 2019年 / 33卷 / 05期
关键词：
neuroepithelial detachment; metastasic melanoma; BRAF inhibitors; MEK inhibitors; pseudovitelliform;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1497 / 1500
页数：4
相关论文
共 50 条
  • [31] Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells
    Kozar, Ines
    Cesi, Giulia
    Margue, Christiane
    Philippidou, Demetra
    Kreis, Stephanie
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2017, 1861 (11): : 2980 - 2992
  • [32] EFFECTIVE COMBINATION THERAPIES WITH MEK INHIBITORS FOR THE TREATMENT OF MUTANT-BRAF LUNG CANCERS
    Matti, Emmanuel
    Ramsdale, Rachel
    Rao, Aparna
    Mcarthur, Grant
    Ferrao, Petranel T.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1067 - S1067
  • [33] Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma
    Buckley, Breea
    Pierce, Bradley
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2018, 31 (05): : 24 - 26
  • [34] The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma
    Dimitriou, Florentia
    Urner-Bloch, Ursula
    Eggenschwiler, Corinne
    Mitsakakis, Nicholas
    Mangana, Joanna
    Dummer, Reinhard
    Urner, Martin
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 215 - 223
  • [35] Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results
    Al-Naesan, Imad
    Krepper, Daniela
    Sparano, Francesco
    Sztankay, Monika
    Efficace, Fabio
    Giesinger, Johannes M.
    MELANOMA RESEARCH, 2025, 35 (02) : 77 - 86
  • [36] Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
    Falkman, Lovisa
    Sundin, Anders
    Skogseid, Britt
    Botling, Johan
    Bernardo, Yvette
    Wallin, Goran
    Zhang, Liang
    Welin, Staffan
    Lase, Ieva
    Mollazadegan, Kazhan
    Crona, Joakim
    UPSALA JOURNAL OF MEDICAL SCIENCES, 2024, 129
  • [37] BRAF Inhibitor Therapy-Related Encephalitis in a Patient with Metastatic Melanoma
    Babacan, Nalan Akgul
    Peguero, Edwin
    Forsyth, Peter
    Eroglu, Zeynep
    ONCOLOGIST, 2021, 26 (10) : E1887 - E1889
  • [38] Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
    Schulz, Alexander
    Raetz, Jennifer
    Karitzky, Paula C.
    Dinter, Lisa
    Tietze, Julia K.
    Kolbe, Isabell
    Kaeubler, Theresa
    Renner, Bertold
    Beissert, Stefan
    Meier, Friedegund
    Westphal, Dana
    CANCERS, 2022, 14 (19)
  • [39] Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma
    Marani, A.
    Gioacchini, H.
    Paolinelli, M.
    Offidani, A.
    Campanati, A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (08) : 555 - 567
  • [40] Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
    Pisanu, Maria Elena
    Maugeri-Sacca, Marcello
    Fattore, Luigi
    Bruschini, Sara
    De Vitis, Claudia
    Tabbi, Eugenio
    Bellei, Barbara
    Migliano, Emilia
    Kovacs, Daniela
    Camera, Emanuela
    Picardo, Mauro
    Jakopin, Ziga
    Cippitelli, Claudia
    Bartolazzi, Armando
    Raffa, Salvatore
    Torrisi, Maria Rosaria
    Fulciniti, Franco
    Ascierto, Paolo A.
    Ciliberto, Gennaro
    Mancini, Rita
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
12345